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ABSTRACT
A 52-year-old woman with rheumatoid arthritis who had been treated with prednisone and hydroxychloroquine for >12 
years presented with chest discomfort and a seizure. She was diagnosed with restrictive cardiomyopathy combined with sick 
sinus syndrome. A myocardial muscle biopsy was performed to identify the underlying cardiomyopathy, which showed 
marked muscle fiber hypertrophy, fiber dropout, slightly increased interstitial fibrous connective tissue, and extensive cyto-
plasmic vacuolization of the myocytes under light microscopy. Electron microscopy of the myocytes demonstrated dense, 
myeloid, and curvilinear bodies. The diagnosis of hydroxychloroquine-induced cardiomyopathy was made based on the 
clinical, hemodynamic, and pathologic findings. This is the first case report describing chloroquine-induced cardiomyopa-
thy involving the heart conduction system. (Korean Circ J 2010;40:604-608)
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Introduction
Chloroquine-induced cardiomyopathy (CICMP) is very 
rare and difficult to diagnose because of the non-specific 
clinical manifestations. A 52-year-old woman presented 
with chest discomfort and a seizure. She had been treated 
with hydroxychloroquine >12 years for the treatment of 
rheumatoid arthritis. The patient was diagnosed with CIC-
MP and sick sinus syndrome. This is the first case report of 
CICMP with sick sinus syndrome, which we present with a 
review of the relevant literature.
Case
A 52-year-old woman was hospitalized for evaluation of a 
2-day-history of chest discomfort. She had rheumatoid ar-
thritis for 13 years and had been treated with hydroxychlo-
roquine for >12 years (total dose, 1,898 grams). In the emer-
gency department, she had a generalized tonic-clonic seizure 
caused by sinus arrest (Fig. 1A). The initial vital signs were as 
follows: blood pressure, 130/80 mmHg; heart rate, 38 beats/
minute; body temperature, 36.4°C; and respiratory rate, 20/
minute. The physical examination revealed a mild degree of 
jugular venous distention, a regular, slow cardiac beat with-
out murmurs, clear lung sounds, and no pitting edema in 
the extremities. The 12-lead ECG showed a junctional rhy-
thm with sinus arrest (Fig. 1B). The laboratory findings in-
cluded a hemoglobin level of 13.1 g/dL and a normal white 
blood cell count with a normal differential cell count. The 
blood urea nitrogen was 27 mmol/L, the serum creatinine 
was 2.02 mg/dL and the C-reactive protein was 0.94 mg/L. 
The antinuclear and anti-double stranded deoxyribonucleic 
acid (DNA) antibodies were negative, while the rheumatoid 
factor was positive. The creatine kinase was 294 UI/L with a 
normal myocardial band fraction. The aspartate aminotrans-Jae Hak Lee, et al.   605
ferase level was 57 U/L, the alanine aminotransferase level 
was 48 U/L, and the alkaline phosphatase level was 49 UI/L. 
Chest radiography demonstrated marked cardiomegaly wi-
thout pulmonary congestion (Fig. 2). Transthoracic echocar-
diography (TTE) revealed a markedly thickened left ven-
tricular (LV) septum and posterior wall thickness, measur-
ing 17.7 mm and 18.8 mm, respectively, with mild LV systolic 
dysfunction (ejection fraction, 44%). A slightly thickened RV 
free wall with mild RV systolic dysfunction was also noted. 
Both atria were enlarged and a mild degree of mitral regur-
gitation was present. The mitral inflow pattern was consistent 
with restrictive physiology. The early mitral inflow (E) veloci-
ty was 90.28 cm/s, the late mitral inflow (A) velocity was 36.77 
cm/s, and the deceleration time was 216.64 milliseconds. The 
E/E’ was 33.4, suggesting a high left ventricular end diastolic 
pressure (Fig. 3). Magnetic resonance imaging (MRI) showed 
diffuse wall thickening of the LV (septal wall thickness at the 
end-diastolic phase, 19 mm) and the RV free wall, suggest-
ing hypertrophic cardiomyopathy. There was a small pericar-
dial effusion. On delayed enhancement, multifocal patchy myo-
cardial enhancement was noted in the lateral and septal walls 
(Fig. 4). The patient underwent myocardial biopsy to deter-
mine the underlying cause of the cardiomyopathy. Light mi-
croscopy showed vacuolated myocytes (Fig. 5A and B). Elec-
tron microscopy revealed abundant intra-myocyte lysosomes 
with numerous large, dense myelin figures occupying large 
portions of the myocyte sarcoplasm. Lysosomal inclusions 
with curvilinear substructures were also noted (Fig. 5C and D). 
There was no evidence of amyloid deposition, myocarditis, 
or an acute vasculitic process. Chloroquine toxicity was diag-
nosed based on the pathologic findings and the hydroxychlo-
roquine was promptly discontinued. A permanent pacemak-
A  
B
Fig. 1. Initial electrocardiogram findings. A: the rhythm strip shows sinus pause. B: the 12-lead electrocardiogram shows a junctional rhythm 
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er was inserted for management of sick sinus syndrome. Four 
months later, the follow-up TTE demonstrated no significant 
interval change in LV systolic function or the LV wall thick-
ness compared with the previous examination. However, LV 
diastolic function improved from restrictive physiology to ps-
eudonormal relaxation. The patient’s rheumatoid arthritis was 
subsequently controlled with low-dose prednisolone and an-
algesics.
 
Discussion
Hydroxychloroquine is a well-known anti-malarial agent 
that is now used for the treatment of rheumatoid arthritis and 
other connective tissue disorders. However, prolonged and 
larger doses of chloroquine are usually required for non-ma-
larial indications.
1-3) These drugs are known to cause a varie-
ty of toxic effects, such as retinopathy,
4) myopathy,
5) neuromyo-
pathy
6) and cardiotoxicity. Conduction system abnormalities 
related to chloroquine include heart block and arrhythmias. 
Chloroquine cardiomyopathy is characterized by biatrial en-
largement, biventricular thickening, and systolic and dia-
stolic dysfunction.
7)8) Chloroquine induces the formation of 
sarcoplasmic myelinoid and curvilinear bodies, which results 
in myocyte dysfunction. Sarcoplasmic accumulation of my-
elinoid and curvilinear bodies expands the myocytes, and as 
a result, the ventricular wall is abnormally thickened.
1)2) Ex-
perimental studies on rabbits and biopsy specimens of hu-
man endomyocardium have established the toxicity of chlo-
roquine in cardiac muscle. Chloroquine is also known to pro-
duce vacuolar myopathy in skeletal muscle,
9)14) and this results 
in a specific ultrastructural pattern of pathologic findings, 
Fig. 2. Chest radiography demonstrated marked cardiomegaly 
without pulmonary congestion.
A  
C  
B  
D  
Fig. 3. Two-dimensional echocardiography reveals severe concentric LV hypertrophy, mild LV systolic dysfunction, a small pericardial effusion, 
and increased RV free wall thickness with mild RV systolic dysfunction. A: parasternal long axis view. B: parasternal short axis view at the mid-
ventricular level. C: magnified apical 4-chamber view. D: mitral inflow view (E velocity, 90.28 cm/s; A velocity, 36.77 cm/s; deceleration time, 
216.64 ms; E/E’: 33.4). LV: left ventricular, RV: right ventricular.
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such as the accumulation of myeloid bodies, glycogen, and 
curvilinear bodies within the skeletal muscles.
15)16) The pro-
posed underlying mechanism is chloroquine-induced phos-
pholipid storage in muscle cells. Chloroquine accumulates 
inside the cells by the action of lysosomes, and intracellular 
chloroquine increases the intralysosomal pH, which results 
in dysfunction of the lysosomal enzymes. Chloroquine in-
duces dysfunction of the lysosomal enzymes by direct bind-
ing, leading to the accumulation of glycogen and phospho-
lipids. Chloroquine also causes acute interference with mi-
tochondrial oxidative metabolism. Accumulated glycogen and 
phospholipids lead to the formation of myelinoid (lamellar) 
and curvilinear bodies that cause dysfunction of myocytes.
17)18)
Diagnosing the underlying cause of idiopathic restrictive 
cardiomyopathy is difficult, although TTE, cardiac MRI, and 
cardiac muscle biopsy can collectively yield essential find-
ings.
19) A large number of patients with restrictive cardiomyo-
pathy have myocardial ischemia associated with chest pain.
20) 
Fig. 5. Myocardial biopsy findings. A and B: light microscopy of the myocardial biopsy specimen showing diffusely enlarged myocytes with ex-
tensive cytoplasmic vacuolization (hematoxylin-eosin staining; A: original magnification ×100, B: ×200 scale bar, 200 μm). C: curvilinear bodies. 
This appearance is typical and characteristic of chloroquine and hydroxychloroquine toxicity. D: the transmission electron microscopy of the skel-
etal muscle biopsy specimen displays central replacement and displacement of the sarcomeres by marked accumulation of secondary lyso-
somes, including myeloid bodies (scale bar 1 μm).
A  
C  
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Fig. 4. Cardiac MRI findings. A: the black-blood coronal axis view on cardiac MRI demonstrates marked concentric left ventricle hypertrophy, 
suggesting hypertrophic cardiomyopathy. Right ventricle wall thickening is also noted and there is a small pericardial effusion. On delayed en-
hancement, signal hyperenhancement after gadolinium administration is observed within the septal wall on the coronal axis view (B) and later-
al wall on the short axis view (C).
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In this case, vacuolated cardiomyocytes and curvilinear 
body formation were observed on light and electron micros-
copy, respectively, which are pathognomic findings of the 
intralysosomal accumulation of lipids. Cervera et al.
1) recom-
mended that a cardiac evaluation with an ECG and an oph-
thalmologic examination should be performed before the long-
term administration of chloroquine. Chloroquine is usually 
not indicated if the patient presents with some cardiac con-
duction disorder in order to prevent cardiomyopathy or com-
plete heart block. It is also recommended that an ECG exam 
should be performed 6 months after chloroquine treatment, 
then annual follow-up is needed when the total dose of chlo-
roquine reaches ≥1,000 grams. There have been a few cases 
of CICMP, which have shown a favorable outcome with im-
provement in left ventricular systolic function after discon-
tinuation of treatment,
6) but most studies have reported per-
sistent signs of cardiac dysfunction and histologic lesions up 
to 9 years after stopping treatment. 
In this case, the patient had a 12-year history of RA, for 
which she had been treated with medications, including hy-
droxychloroquine. She did not complain of symptoms of heart 
failure and her symptoms were mainly due to sick sinus syn-
drome. Her echocardiograpic evaluation manifested the clas-
sic findings of restrictive cardiomyopathy by infiltrative dis-
ease, including biventricular hypertrophy, restrictive mitral 
and pulmonary vein inflow, and an increased LV end-diastol-
ic filling pressure. Even though the follow-up echocardio-
graphic parameters of systolic function did not show signifi-
cant improvement 4 months after discontinuation of hydroxy-
chloroquine, her symptoms had improved substantially. 
Further, the parameters of diastolic function improved, which 
suggested the possible recovery of myocardial function. The 
patient will be followed on a regular basis. 
Herein we have reported a case of CICMP with a conduc-
tion disorder, in which the patient manifested typical find-
ings of infiltrative restrictive cardiomyopathy by TTE and MRI. 
Her symptoms were successfully treated with the implanta-
tion of a permanent pacemaker. The myocardial biopsy find-
ings and the patient’s medical history confirmed the diagno-
sis. The cardiac function of patients who need long-term ad-
ministration of chloroquine should be carefully monitored. 
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